HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OraLabs

This article was originally published in The Rose Sheet

Executive Summary

Third quarter revenues fell nearly 4% to $2.8 mil., a loss of $.08 per share, while net loss was $360,205, compared to net income of $33,431 in 2003. Parker, Colo. firm attributes lackluster results to expenses associated with the company's relocation, which contributed to reduced gross profit and a reported loss. OraLabs remains optimistic, noting, "the company is going into its busy season and we are hopeful that our expansion investments will pay off." OraLabs manufacturers lip care products such as ChapIce, Chap Grip and Soothe & Shine, as well as Ice Drops breath drops and sprays...

You may also be interested in...



Polish Industry Fighting Against Advertising Tax On Supplements

Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.

England’s NICE Future Proofs Approach To Using Data

UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.

Krka Responds To Romanian Allegations

Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.

UsernamePublicRestriction

Register

RS012642

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel